In:
Cancer, Wiley, Vol. 117, No. 6 ( 2011-03-15), p. 1262-1271
Abstract:
A pooled analysis of 9 extensive stage small‐cell lung cancer studies found that progression‐free survival (PFS) is an improved endpoint over tumor response at predicting overall survival (OS) and subsequent survival. PFS also shows promise as a potential surrogate for OS, but further validation is needed using data from a larger number of randomized phase 3 trials.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2011
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1